Breaking News

Boehringer to Acquire NBE-Therapeutics in €1.2B Transaction

Gains iADC platform and potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors.

By: Contract Pharma

Contract Pharma Staff

PPF Group, an international investment group, has signed an agreement to sell its stake in NBE-Therapeutics to Boehringer Ingelheim. NBE-Therapeutics is using its iADC platform to develop potential best-in-class antibody-drug conjugate (ADC) therapies for the treatment of solid tumors. The lead program NBE-002, an iADC targeting ROR1, entered the Phase I testing in 2020. The transaction, valued at €1.18 billion, is comprised of an upfront payment to NBE’s shareholders as well as contingent c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters